Login
Contact

Explore

Explore

About
  • People and Partners
  • TRI Building
  • Reconciliation Action Plan
  • Strategic Plan
  • TRI Foundation
  • Careers
Research
  • Collaborate
  • Discovery
  • Translate
  • Engage
  • Research Areas
Clinical
  • Translational Trials
  • Clinical Research Facility
  • TRI at Children’s
Industry
  • TRI Incubator
  • The Precinct
  • Residents
Manufacture
  • New cGMP Facility
Facilities
  • Cleanroom
  • Flow Cytometry
  • Histology
  • Microscopy
  • Proteomics
  • Preclinical Imaging
  • Biological Research
  • Gnotobiotics
  • Human Immune Model
Get Involved
  • Health Consumers
  • SPARQ-ed
Resources
  • News
  • Events
  • Case Studies
  • Grants and Funding
  • Education and Training

+61 7 3443 7000info@tri.edu.au37 Kent Street, Woolloongabba QLD 4102 Australia

Acknowledgement of Country

TRI acknowledges the traditional custodians of the land we are on today, the Turrbal and Jagera people and we recognise their continuing connection to land, waters and community. We pay deep respect to them and their cultures; and to Elders past, present and emerging.

© Translational Research Institute Pty Ltd atf the Translational Research Institute Trust|ABN: 58 155 991 662
Privacy policy|Terms of Use|Contact Us
TRI · Facilities

Facilities

World-class capabilities and infrastructure

TRI’s facilities provide access to world-class capabilities for researchers and clinicians at the interface of science, medicine, and industry. As part of TRI’s unique precinct, our highly specialised facility equipment, staff, and emerging technologies are designed to support and create opportunities for advancing medical research.

For all general enquiries regarding TRI’s Facilities, please contact:

Core Facilities – Tess Vogts at corefacilities@tri.edu.au
Cleanroom – Arman Ergenekon at cleanroom@tri.edu.au

Flow Cytometry
Microscopy
Cleanroom
Preclinical Imaging
Histology
Proteomics
Biological Research
Gnotobiotics
Human Immune Model
Clinical Research Facility (CRF)
TRI at Children’s (TRIC)

Case Studies

Genomics

TRI’s new Musculoskeletal Genomics Group

Human Immune Models
Humanised immune models advancing therapeutic development

TRI has a partnership with The Jackson Laboratory to establish Australia’s first immune-humanised preclinical model generation and distribution facility.

MicrobiomeTranslational Trials
Transforming healthcare with microbiome research

TRI-based researchers from QUT are progressing our understanding of the human microbiome and its role in human health and disease.

Research Support
Federal funding for TRI-based researchers

TRI-based researchers from The University of Queensland, Mater Research and Queensland University of Technology are sharing in more than $12million in the latest round of National Health and Medical Research Council (NHMRC) funding.

Breast Cancer
Imaging tech could give better breast cancer risk estimation

Australian women could better gauge their breast cancer risk through new imaging technology, without radiation that comes with mammography.

CancerImmunology
QUT scientists developing precision treatment to boost cancer patients’ immune systems

QUT scientists at the Translational Research Institute (TRI) are harnessing a new class of pharmaceutical compounds, known as aptamers, to develop a drug to boost the immune system’s ability to fight cancer.

Skin cancer
$10M to boost advanced melanoma imaging for Australia

Professor H. Peter Soyer has been awarded $10 million for the Australian Centre of Excellence in Melanoma Imaging and Diagnosis at TRI.

TRI Announcement
TRI and Vaxxas celebrate major milestone

Vaxxas has produced its 100th batch of needle‐free vaccine patches at TRI – technology that may soon help protect Australians against infectious diseases.

Immunology
New Human Immune Models set to accelerate preclinical drug development

TRI-based scientists from Mater Research are developing research models that more accurately replicate the human immune system.

Translational Trials
Princess Alexandra Hospital home to world first prostate cancer trial

A radiopharmaceutical company based at TRI is part of a world-first trial of a treatment for difficult-to-treat cancers that have spread in the body.

Come on a site tour of our new facility

Due to open early 2026 and proudly funded by the Queensland Government and TRI, our new translational manufacturing facility will support early-phase start-up biotech companies to establish, build, test and develop their products. Take the site tour with our General Manager, Translational Biomedical Manufacturing David Crowley and Project Manager James Dane from Built.

Cystic FibrosisTRI Announcement
Prestigious international award for TRI CEO

TRI CEO Professor Scott Bell has been recognised for his outstanding contribution to cystic fibrosis with a prestigious international award.

Prostate Cancer
Advancing prostate cancer diagnostics

Critical insights into prostate cancer have been uncovered, with researchers using them to identify therapeutic targets and developing a diagnostic tool.

Cancer
A new era in cancer diagnosis and treatment

Researchers are using theranostics to detect and treat some of the deadliest cancers, including pancreatic, ovarian, and bladder cancer.

CancerGenetics
Genes identified for aggressive melanoma

Researchers from The University of Queensland and The Alfred hospital in Melbourne have identified gene variants which may contribute to people being at higher risk for nodular melanoma.

Cancer
New target to beat cancer drug resistance

The University of Queensland researchers have identified a novel drug target with the potential to overcome drug resistance and prevent tumour regrowth in cancer patients.

MicrobiomeNeuroscience
Parkinson’s research targets gut microbiome

Researchers based at TRI are developing Parkinson’s disease treatments by targeting the gut microbiome.